|
 In the latest salvo against high U.S. prices for important
medicines, the 18-month Senate Finance Committee investigation into
the cost of Gilead's Sovaldi and follow-on combination treatment
Harvoni accused the company of putting maximizing revenue ahead of
patient access.
The vast majority of the more than 700,000 people on state Medicaid
programs for the poor with hepatitis C are still awaiting treatment,
the probe found.
"It was always Gilead's plan to maximize revenue, and affordability
and accessibility was an afterthought," Senator Ron Wyden, Democrat
from Oregon, said at a news conference to announce the findings
along with Iowa Republican Senator Chuck Grassley.
The senators said Sovaldi and Harvoni prices did not reflect the
cost of research and development or the $11 billion Gilead paid for
Pharmasset to acquire the drugs, but purely a desire to maximize
profit.
Sovaldi was introduced at a list price of $84,000 for a course of
treatment, or about $1,000 per pill, creating a furor over its cost.
The Gilead drugs represent a vast improvement over prior treatments
that had far lower cure rates and many troublesome side effects.
While those older treatments were also expensive, they did not cause
a similar burden on healthcare budgets as thousands of patients put
off treatment while waiting for improved new drugs that promised a
cure.
"If Gilead's approach to pricing is the future of how blockbuster
drugs are launched, it will cost billions and billions of dollars to
treat just a fraction of patients," said Wyden, the Finance
Committee's ranking member.
As an example, the report said Indiana's Medicaid program spent $40
million to treat 462 people.
In 2014 alone, Medicare and Medicaid combined to spend more than $5
billion on Sovaldi and Harvoni before rebates, the probe found.
[to top of second column] |
Gilead, in a statement, said it respectfully disagrees with the
conclusions of the report.
"With the rebates and discounts now in place, the prices today are
less than the cost of prior regimens," the company said, noting that
its treatments reduce the long-term costs associated with managing
chronic hepatitis C, such as by preventing liver failure or the need
for transplants.
The high price of U.S. prescription medicines has become a major
issue in the campaign for the November 2016 presidential election,
with Democratic candidates Hillary Clinton, Bernie Sanders and
Martin O'Malley calling for changes to limit costs to patients.
"If America is to cure Alzheimer's, cancer, diabetes and HIV in the
years ahead, these cures must not be unaffordable and beyond the
reach of most Americans," Wyden said.
Some newer cancer treatments cost $150,000 or more a year.
(Reporting by Bill Berkrot; Editing by David Gregorio)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
